[Corrigendum] Effect of duty cycles of tumor‑treating fields on glioblastoma cells and normal brain organoids

Ye, Eunbi; Lee, Jung; Lim, Youn-kyung; Yang, Seung Ho; Park, Sung Min

doi:10.3892/ijo.2022.5397

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other TTFields-appropriated 3D models exist which have been used to test treatment responses using rodent-grown, patient-derived orthotopic slices and/or organoids [ 40 , 41 , 42 ]. Such 3D models present multiple advantages when compared to 2D cultures, such as mimicking 3D brain architecture, the establishment of complex cell–cell interactions and the possession of ECM components, and they can therefore reliably measure treatment responses.…”

Section: Discussionmentioning

confidence: 99%

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity

Jones,

Vanderlinden,

Rominiyi

et al. 2024

Cancers

View full text Add to dashboard Cite

Glioblastoma is an aggressive, incurable brain cancer with poor five-year survival rates of around 13% despite multimodal treatment with surgery, DNA-damaging chemoradiotherapy and the recent addition of Tumour Treating Fields (TTFields). As such, there is an urgent need to improve our current understanding of cellular responses to TTFields using more clinically and surgically relevant models, which reflect the profound spatial heterogeneity within glioblastoma, and leverage these biological insights to inform the rational design of more effective therapeutic strategies incorporating TTFields. We have recently reported the use of preclinical TTFields using the inovitroTM system within 2D glioma stem-like cell (GSC) models and demonstrated significant cytotoxicity enhancement when co-applied with a range of therapeutically approved and preclinical DNA damage response inhibitors (DDRi) and chemoradiotherapy. Here we report the development and optimisation of preclinical TTFields delivery within more clinically relevant 3D scaffold-based primary GSC models of spatial heterogeneity, and highlight some initial enhancement of TTFields potency with temozolomide and clinically approved PARP inhibitors (PARPi). These studies, therefore, represent an important platform for further preclinical assessment of TTFields-based therapeutic strategies within clinically relevant 3D GSC models, aimed towards accelerating clinical trial implementation and the ultimate goal of improving the persistently dire survival rates for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity

Jones,

Vanderlinden,

Rominiyi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Development of glioblastoma organoids and their applications in personalized therapy

et al. 2023

View full text Add to dashboard Cite

Glioblastomas (GBMs) are the brain tumors with the highest malignancy and poorest prognoses. GBM is characterized by high heterogeneity and resistance to drug treatment. Organoids are 3-dimensional cultures that are constructed in vitro and comprise cell types highly similar to those in organs or tissues in vivo, thus simulating specific structures and physiological functions of organs. Organoids have been technically developed into an advanced ex vivo disease model used in basic and preclinical research on tumors. Brain organoids, which simulate the brain microenvironment while preserving tumor heterogeneity, have been used to predict patients’ therapeutic responses to antitumor drugs, thus enabling a breakthrough in glioma research. GBM organoids provide an effective supplementary model that reflects human tumors’ biological characteristics and functions in vitro more directly and accurately than traditional experimental models. Therefore, GBM organoids are widely applicable in disease mechanism research, drug development and screening, and glioma precision treatments. This review focuses on the development of various GBM organoid models and their applications in identifying new individualized therapies against drug-resistant GBM.

show abstract

[Corrigendum] Effect of duty cycles of tumor‑treating fields on glioblastoma cells and normal brain organoids

Cited by 2 publications

References 0 publications

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity

Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity

Development of glioblastoma organoids and their applications in personalized therapy

Contact Info

Product

Resources

About